Kibo Ventures

Kibo Ventures is one of the larger and longer-established Spanish venture firms, operating from Madrid with a multi-stage capacity that few Iberian funds can match. The firm has been backing Spanish technology founders for over a decade, and its current activity in AI, cybersecurity, and digital health reflects an evolution rather than a pivot.

The healthcare thesis covers digital health and AI/ML in healthcare, with the disclosed portfolio anchor being Acurable, the Spanish remote diagnostic company. That portfolio reference is informative: Kibo is comfortable with clinically grounded software companies that have credible regulatory pathways and real diagnostic or therapeutic applications, rather than purely workflow-focused tools. Founders building in similar territory will find more shared language and pattern recognition than founders working on horizontal SaaS that happens to apply to healthcare.

Kibo invests across Pre-Seed, Seed, Series A, Series B, and Series C, with initial checks of one to five million dollars and significant follow-on capacity through subsequent funds. That multi-stage continuity matters in the Spanish context, where Series A and B financing markets are thinner than in Germany or France, and the ability to anchor multiple rounds from the same fund materially reduces financing risk for founders. The geographic focus is Spain with active pan-European participation, and the firm has the relationships to support international expansion when warranted.

The team is built around partners with backgrounds in operating, investing, and scaling Spanish technology companies. Specific partner names are not provided in the source material, and founders should clarify which partner leads healthcare directly and how multi-stage continuity is handled in practice.

The right founders for Kibo are Spanish digital health and health AI teams with credible international ambition, where the firm’s local depth and multi-stage continuity create genuine fit. The wrong founders are deeply clinically regulated device or therapeutics programs, where Kibo’s software-leaning thesis may not provide the specialist support those companies need. Founders should arrive with a clear view of the Spanish commercial path, realistic assumptions about how Iberian healthcare buyers behave, and a credible plan to extend into at least one or two additional European markets. Kibo rewards founders who treat Spain as a serious commercial market rather than a launchpad, and tends to engage seriously with the operational realities of building from Madrid or Barcelona.